Epsilon M&A Deal Report - Novel Pharma SL (Secuvita)

Transaction Multiples for the Valuation of Private Companies

VITA 34 International > Novel Pharma SL (Secuvita)

Announced Date : 12 May 2010

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : VITA 34 International

Target: Novel Pharma SL (Secuvita)

Target Country: Spain

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Founded in June 2004, Secuvita collects, ...

No EMAT : 71420

Transaction multiples available

EV/Sales EV/Gross Profit EV/EBITDA EV/EBIT Eq/PBT P/E Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating *

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226

Example of comparable transactions on EMAT (same sub-sector):

Date Acquirer Target Country Multiples See details
04/02/2015 Shofu Merz Dental Germany 0
03/11/2010 Cryo-Save Tissue Bank Cryo Center Bulgaria AD (TBCCB) Bulgaria 0

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report
About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

Subscribe to EMAT database